Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 24, 2009

Bio-Rad and Bruker Ally to Develop Biomarker Discovery Tools

  • Bio-Rad Laboratories and Bruker are combining technologies for high-throughput protein profiling and identification. The exclusive agreement includes the development and marketing of new products based on Bio-Rad’s surface-enhanced laser desorption/ionization (SELDI) technology in combination with Bruker’s matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF/TOF) mass spectrometers.

    The products will provide solutions for biomarker discovery, in particular, the detection and high-confidence identification of intact peptides and proteins under 30 kilodaltons. These are challenging for currently available technologies to identify, according to the companies.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »